INTRODUCTION AND OBJECTIVES:
The impact of delaying radical prostatectomy (RP) among patients diagnosed with clinically localized prostate cancer (PCa) for whom active surveillance is not an option is unclear. Therefore, we sought to evaluate the impact of length of time from diagnostic biopsy to RP on oncologic outcomes among men diagnosed with unfavorable intermediate to very high-risk PCa.
METHODS: We performed a retrospective review of men with a diagnosis of Gleason grade group (GG)! 3 PCa on a biopsy who underwent RP within 6 months of diagnosis at our institution between 2005 and 2018. We assessed patient demographics and pre-biopsy disease characteristics. We categorized time between biopsy and RP into two intervals (<3 months and 3-6 months). For each GG, we compared receipt of adjuvant therapy, pathological outcomes at RP [positive surgical margin (PSM), extraprostatic extension (EPE), seminal vesicle invasion (SVI), and lymph node involvement (LNI)], risk of 2-and 5-year biochemical recurrence-free survival (BCRFS), and 2-, 5-, and 10-year metastasis-free survival (MFS) between patients who underwent RP <3 months versus 3-6 months after diagnosis.
RESULTS: Among 2,303 men who met study inclusion criteria, 1,244 (54%) had GG3, 608 (26%) had GG4, and 451 (20%) had GG5 disease. 72% underwent RP <3 months after diagnosis. For each diagnostic GG, there was no significant difference in rates of adjuvant therapy, PSM, EPE, SVI, or LNI in men who had RP <3 months versus 3-6 months after diagnosis. 1,568 men had follow-up post-RP for >1 year. For each diagnostic GG, there was no significant difference in 2-and 5-year BCRFS between patients who had RP <3 months versus 3-6 months after diagnosis (GG3: 78% vs. 83% and 69% vs. 66%, respectively, p[0.6; GG4: 68% vs. 74% and 51% vs. 57%, respectively, p[0.4; GG5: 58% vs. 74% and 48% vs. 54%, respectively, p[0.2). Similarly, for each diagnostic GG, there was no significant difference in 2-, 5-, and 10-year MFS between patients who had RP <3 months versus 3-6 months after diagnosis, although we were not able to calculate 10-year MFS for patients with GG5 disease due to limited follow-up in that group (GG3: 98%, 92%, and 84% vs. 97%, 95%, and 91%, respectively, p[0.4; GG4: 97%, 90%, and 72% vs. 94%, 91%, and 81%, respectively, p[0.8; GG5: 89% and 81% vs. 91% and 71%, respectively, p [ 0.9).
CONCLUSIONS: Waiting for RP up to 6 months after diagnosis is not associated with adverse outcomes among patients with unfavorable intermediate-risk to very high-risk PCa.
Source of Funding: none

PD40-10 MORTALITY FOLLOWING RADICAL PROSTATECTOMY (RP) OR INTENSITY MODULATED RADIATION THERAPY (IMRT) FOR LOCALIZED PROSTATE CANCER (PCA) e AN ANALYSIS OF THE CDC PROSTATE CANCER DATA QUALITY AND PATTERNS OF CARE STUDY (CDC POC-BP)
Kenan Celtik*, Houston, TX; Christopher Wallis, Toronto, Canada; Mary Lo, Ann Hamilton, Los Angeles, CA; Steven Fleming, Lexington, KY; Xiao-Cheng Wu, New Orleans, LA; Roger Anderson, Charlottesville, VA; Brian Miles, Raj Satkunasivam, Houston, TX INTRODUCTION AND OBJECTIVES: Comparative effectiveness of RP and IMRT for PCa have been poorly studied, and limited by poor measurement of patient comorbidities. We sought to examine survival differences using a population-based cohort with robust data on comorbidities.
METHODS: The CDC POC-BP study was conducted between 2007-2009 and involved medical record abstraction of 8,229 cases of localized PCa diagnosed in 2004 across the CDC National Program of Cancer Registries. We identified 3019 RP and 667 IMRT patients. Propensity score matching (PSM) was used to balance sociodemographic and clinical characteristics, including comorbidities assessed by the Adult Comorbidity Evaluation-27 (ACE-27) score, between patients receiving RP and IMRT. We compared overall survival (OS) and prostate cancer specific survival (CSS) between RP and IMRT using Kaplan Meier curves and Cox proportional hazard analyses. We performed a pre-specified subgroup analysis in patients with National Comprehensive Cancer Network (NCCN) high risk, localized PCa treated with RP (n[89) and IMRT (n[95).
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